40 related articles for article (PubMed ID: 18954749)
1. Beyond chemotherapy: new agents for targeted treatment of lymphoma.
Younes A
Nat Rev Clin Oncol; 2011 Feb; 8(2):85-96. PubMed ID: 21151205
[TBL] [Abstract][Full Text] [Related]
2. Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma.
Frieboes HB; Smith BR; Wang Z; Kotsuma M; Ito K; Day A; Cahill B; Flinders C; Mumenthaler SM; Mallick P; Simbawa E; Al-Fhaid AS; Mahmoud SR; Gambhir SS; Cristini V
PLoS One; 2015; 10(6):e0129433. PubMed ID: 26061425
[TBL] [Abstract][Full Text] [Related]
3. Primary gastrointestinal lymphoma.
Ghimire P; Wu GY; Zhu L
World J Gastroenterol; 2011 Feb; 17(6):697-707. PubMed ID: 21390139
[TBL] [Abstract][Full Text] [Related]
4. Five steps for structural reform in clinical cancer research.
Matheson A
Am J Public Health; 2010 Apr; 100(4):596-603. PubMed ID: 20167889
[TBL] [Abstract][Full Text] [Related]
5. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
9. New drugs for the treatment of lymphoma.
Paoluzzi L; Kitagawa Y; Kalac M; Zain J; O'Connor OA
Hematol Oncol Clin North Am; 2008 Oct; 22(5):1007-35, x. PubMed ID: 18954749
[TBL] [Abstract][Full Text] [Related]
10. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
O'Connor OA
J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030
[TBL] [Abstract][Full Text] [Related]
11. [Chronic myeloid leukemia in the 21st century: biology and treatment].
Chávez-González MA; Ayala-Sánchez M; Mayani H
Rev Invest Clin; 2009; 61(3):221-32. PubMed ID: 19736811
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]